474654-85-8

Upstream product

• 474655-13-5 4-{(7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-[4-(4-phenyl-piperazin-1-yl)-butyl]-amino}-butyronitrile 
• 92-54-6 4-phenyl-1-piperazine 
• 40255-41-2 4-(4-phenylpiperazin-1-yl)butan-1-amine 
• 115338-24-4 2-[4-(4-phenylpiperazin-1-yl)butyl]-1H-isoindole-1,3(2H)-dione 
• 444145-81-7 (7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-[4-(4-phenyl-piperazin-1-yl)-butyl]-amine 

Downstream Products

• 477788-84-4 7-Methoxyl-2-[N-(4-benzoylaminobutyl)-(N-(4-phenylpiperazin-1-yl)-butyl)amino]tetralin 
• 477789-01-8 4-Chloro-N-[3-(2-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino}-ethyl)-phenyl]-benzenesulfonamide 

Relevant academic research and scientific papers

Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity

Hybrid compounds containing in aminotetralin moiety or a heterocyclic and/or open chain analog thereof linked through an alkylene group to an aryl ring system-substituted piperidiene moiety exhibit high levels of CNS activity, in some cases exhibiting especially high relative binding efficiencies between D3 and D2 dopaminergic receptor subtypes.

A novel series of hybrid compounds derived by combining 2-aminotetralin and piperazine fragments: Binding activity at D2 and D3 receptors

A series of 7-hydroxy-2-[N-alkyl-(N-(4-phenylpiperazine)-alkyl)amino]tetralins was developed based on a novel hybrid approach that combined 2-aminotetralin and arylpiperazine pharmacophoric moieties. Our preliminary study revealed that a four-methylene bu